How is CJC-1295 DAC chemically defined for identity testing?
When a laboratory evaluates a named GHRH analogue, the first task is to define the intended chemical entity. In the peer-reviewed chemical literature, CJC-1295 was identified as a long-lasting GRF analogue within a series of human GRF(1-29)–albumin bioconjugates that present a maleimide handle capable of forming a covalent adduct with albumin (PMID:15817669). For procurement and quality-control purposes that description is a structural specification, not a use claim: the DAC-bearing molecule is a tetrasubstituted GRF(1-29) analogue plus a maleimidopropionyl linker. Lots labelled only “CJC-1295” may be the DAC construct, the same core sequence without the maleimide (often marketed as “no-DAC”), or an unrelated truncated GRF fragment. Those entities have different molecular masses, related-substance profiles and HPLC retention times.
Identity testing therefore starts with a written sequence and a theoretical monoisotopic mass for the DAC-bearing chain, including the maleimidopropionyl increment and the stated C-terminal residue. The CoA should state whether the reported mass is monoisotopic or average, the ionisation mode, and the observed adduct. A mass that matches tetrasubstituted GRF(1-29) without the maleimide increment is evidence that the vial is not the DAC entity, regardless of the trade name on the label. A mass consistent with the DAC construct should still be supported by chromatographic purity and, where tandem mass spectrometry is available, by fragment ions that localise the linker.
Maleimide-bearing peptides generate characteristic related substances, including ring-opened maleamic acid, hydrolysed linker, incomplete coupling at the lysine handle, and deletion sequences around the substitution sites. A CoA that reports a single area-percent purity figure without a related-substance table cannot show whether the main peak is the intact maleimide or a hydrolysed variant. Australian buyers comparing local stock should request the chromatogram, the mass spectrum, the integration method (wavelength, baseline, peak-valley rule) and the lot code printed on both the CoA and the vial. Receiving laboratories should also archive the theoretical mass calculation, including the elemental formula of the salt-free chain, so a later analyst can repeat the comparison without reconstructing the sequence from a trademark.
How do HPLC and mass spectrometry separate DAC-bearing CJC-1295 from no-DAC listings?
Reversed-phase HPLC with ultraviolet or diode-array detection is the workhorse purity method for synthetic peptides, but it does not, by itself, prove that the main peak is the DAC construct. Retention time is method-dependent: column chemistry, ion-pair reagent (commonly trifluoroacetic acid or formic acid), gradient slope, temperature and sample solvent all shift apparent purity and the elution order of related substances. A receiving laboratory should treat the supplier chromatogram as a batch record to be interpreted against stated method parameters, not as a portable identity tag. Diode-array peak-purity tools (ratiograms, purity angle versus purity threshold, match factor) can flag co-elution, yet they cannot assign elemental composition. Orthogonal mass spectrometry is required to attach a mass to the main peak and to major impurities.
Electrospray ionisation on a quadrupole or time-of-flight analyser is the usual intact-mass method. The spectrum of a few-kilodalton analogue is a charge-state envelope; deconvolution should be documented so that another analyst can reproduce the reported mass. Tandem spectra, where recorded, can confirm the tetrasubstituted GRF core and, in favourable cases, the lysine that carries the maleimidopropionyl group. Published confirmatory workflows have used liquid chromatography–tandem mass spectrometry after selective sample preparation, including immunoaffinity capture and immuno-polymerase-chain-reaction screening followed by LC-MS/MS confirmation (PMID:21871962; PMID:30489688; PMID:30938069). Those papers are detection-method references showing that the DAC-bearing sequence is analytically distinguishable from other GHRH analogues; they are not purchasing instructions.
Neighbouring catalogue names must be resolved the same way. Tesamorelin is a hexenoyl-modified GHRH(1-44) analogue and differs in chain length and N-terminal chemistry, whereas unmodified GRF(1-29) lacks both the tetrasubstitution pattern and the DAC. “CJC-1295 no DAC” shares some core substitutions but not the maleimide mass increment. Ask whether the HPLC method was challenged with a no-DAC core and a hydrolysed-maleimide marker, and keep system-suitability chromatograms (blank, reference, resolution mixture) in the batch record. A single HPLC area-percent value cannot separate those entities if the method was never shown to resolve them, so the mass of the main peak should be collected on-line or from a collected fraction and reported with the chromatogram.
Where to buy CJC-1295 Australia: which CoA fields prove DAC identity?
A transactional search for where to buy CJC-1295 Australia is only as good as the documents that travel with the vial. Minimum CoA fields for a DAC-bearing research lot are: chemical name and sequence (or a sequence code that unambiguously includes the maleimidopropionyl lysine), theoretical and measured mass, chromatographic purity with wavelength and integration rule, a related-substance list or annotated chromatogram, counter-ion identity and content where measured, appearance, net peptide content (amino-acid analysis or equivalent), water content if Karl Fischer was performed, lot number, a documentation date, and the testing laboratory’s identity. The vial label must reproduce the lot number exactly. A CoA lot that does not match the label is not a usable batch record.
Net peptide content and counter-ion are frequently omitted on grey-market paperwork, yet they determine how many milligrams of peptide, as opposed to peptide-plus-salt-plus-water, are in the container. Trifluoroacetate and acetate lots are not interchangeable on a mass-balance basis. If two Australian quotations are compared on a per-vial price without peptide-content and counter-ion data, the comparison is chemically undefined. Request the same fields for every lot, including multi-vial orders drawn from one bulk synthesis, so that vial-to-vial consistency can be checked against a single batch report.
Traceability should extend beyond the CoA PDF. Useful supporting files include the chromatogram, the mass spectrum with a calibration reference, a method identifier, and a packing list that ties each vial to the lot. Local Australian stock with tracked dispatch makes that paper trail easier to audit because the receiving laboratory can reconcile the carrier consignment number with the lot when the parcel arrives, without waiting on an overseas broker. Regulatory framing remains research-only: a CoA is not a therapeutic-goods registration, and laboratories remain responsible for institutional approvals and for restricting material to laboratory research. Supplier evaluation should also ask whether DAC and no-DAC catalogue codes are segregated so that a warehouse pick cannot substitute one for the other, and whether a lot-specific chromatogram—not a representative image—will be re-issued if the original PDF is illegible.
How have published methods identified CJC-1295 in unknown preparations?
Unknown or poorly labelled vials are a documented analytical problem. Henninge and co-workers identified CJC-1295 in an unknown pharmaceutical preparation by applying mass-spectrometric and chromatographic characterisation to a material whose label could not be trusted (PMID:21204297). That work is directly relevant to research procurement: a trade name on a website is not identity, and the receiving laboratory must treat an unexpected mass or retention time as a different substance. Reviews of GHRH synthetic-analogue detection have expanded the toolbox to high-resolution mass spectrometry, improved clean-up and analogue-specific transitions (PMID:34665524). These papers establish that DAC-bearing GHRH analogues are identifiable as chemical entities when orthogonal methods are used, and that mislabelled preparations occur in circulation.
Confirmatory strategies published for plasma illustrate the same identity logic even though they were written for anti-doping laboratories rather than incoming-goods inspection. Immunoaffinity purification concentrates the peptide before LC-MS and yields clearer product-ion spectra (PMID:21871962). An immuno-polymerase-chain-reaction screen has been described for CJC-1295 and other GHRH analogues, with LC-MS/MS used to confirm presumptive findings (PMID:30489688; PMID:30938069). A research receiving laboratory will not usually copy those matrix methods, but it can copy the decision tree: a selective screen, an orthogonal mass confirmation, and a written rule for what counts as the DAC-bearing sequence.
Interpretation should be conservative. Matching a single precursor ion is weaker than matching a precursor plus diagnostic fragments plus retention against a characterised reference. If the laboratory lacks a qualified reference standard, the supplier CoA mass and chromatogram become the provisional reference and should be archived with the working sample. Discrepancies worth investigating include a mass consistent with the no-DAC core, a mass consistent with unsubstituted GRF(1-29), extra hexenoyl mass suggesting a tesamorelin-type analogue, and a dominant related substance at plus eighteen daltons that may indicate maleimide hydrolysis. Those are identity outcomes that determine whether the lot is the chemical the protocol named.
What supplier checks separate a documented Australian DAC lot from a catalogue synonym?
Purchase intent for research peptides in Australia is often expressed as “where to buy”, “supplier”, or “for sale”, yet the discriminating questions are operational. Does the vendor publish separate catalogue codes for DAC and no-DAC? Is the maleimidopropionyl residue drawn in the structure or spelled in the sequence line, or is the buyer left to infer it from a trademark? Are chromatograms lot-specific? Is net content reported? Can the warehouse confirm that the picked lot is Australian-held stock rather than a drop-ship from an unnamed third party? Tracked dispatch with a lot-level packing list is a documentation control; it is not a substitute for identity testing, but it does allow a non-conforming vial to be quarantined against a named consignment.
Bulk or multi-vial orders amplify the cost of a synonym error. If many vials share one lot, a single orthogonal HPLC-MS check can qualify the set, provided the packing list and the CoA carry the same lot code and the vials are visually consistent (lyophilised cake, closure, label print). If each vial is a different lot, each CoA is required and the laboratory should not assume that purity, counter-ion or maleimide integrity are equivalent. Ask whether mixed-lot substitution is permitted when one lot is exhausted, and record the answer in the purchase file beside the specification.
ClaraScience positions CJC-1295 research material as a documented chemical from local Australian stock, with batch documentation and tracked dispatch. Place those artefacts next to any competing quotation: DAC sequence line, measured mass, HPLC chromatogram, related-substance annotation, counter-ion, peptide content, lot-code concordance, and a research-only statement. A higher area-percent purity is not automatically superior if the method is undisclosed, and a lower price is not equivalent if peptide content is missing. Write a one-page incoming specification, archive PDFs under the lot number, and reject listings that cannot state whether the material is DAC or no-DAC. The laboratory’s protocol names a molecule; receiving inspection either confirms that molecule or it does not, irrespective of how prominently a listing ranks for a where-to-buy query.
Order Cjc 1295 with documentation
If this guide helped you evaluate Cjc 1295 for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Cjc 1295 card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Does “CJC-1295” on an Australian catalogue always mean the DAC-bearing analogue?
No. The same trade name is used for the maleimidopropionyl DAC construct and for no-DAC tetrasubstituted GRF(1-29). Identity is the sequence plus the linker mass, reported on a lot-specific CoA with HPLC and mass spectrometry. Ask the supplier to state DAC or no-DAC in chemical terms before you order, and match the lot code on the vial to the CoA.
Which CoA fields should I check when deciding where to buy CJC-1295 Australia?
Check sequence (including maleimidopropionyl lysine), theoretical and measured mass, HPLC purity with wavelength, related-substance annotation, counter-ion, net peptide content, lot number concordance with the vial, and the testing laboratory’s identity. Local Australian stock, tracked dispatch and a packing list that repeats the lot code complete the paper trail. Research use only; a CoA is not a medicine registration.
Can HPLC area-percent purity confirm that a lot is DAC-bearing CJC-1295?
No. Area-percent purity describes the main peak under a stated method; it does not assign elemental composition or localise the maleimide. Intact mass, and tandem fragment ions where available, are required to distinguish DAC, no-DAC, GRF(1-29) and tesamorelin-type analogues. Peak-purity algorithms may flag co-elution but still need orthogonal mass spectrometry.
How do published papers help a receiving laboratory verify CJC-1295?
Henninge and co-workers showed that CJC-1295 can be identified in an unknown preparation by chromatography and mass spectrometry (PMID:21204297). Detection reviews and confirmatory LC-MS/MS or immunoaffinity methods show the analogue is distinguishable from related GHRH sequences (PMID:34665524; PMID:21871962). Use those papers as method references, not as purchasing or protocol templates.
What is the difference between DAC CJC-1295 and tesamorelin on a CoA?
Tesamorelin is a hexenoyl-modified GHRH(1-44) analogue; DAC-bearing CJC-1295 is a tetrasubstituted GRF(1-29) analogue with a maleimidopropionyl linker. Chain length, N-terminal chemistry and intact mass differ. A supplier should not substitute one catalogue code for the other. Compare sequence lines and measured masses, not trade names.
What should a laboratory do if the measured mass matches no-DAC rather than DAC?
Quarantine the vial, retain the CoA and packing list, and record the measured mass against the theoretical DAC and no-DAC masses. Do not relabel the material as the protocol substance. Raise a non-conformance with the supplier using the lot code. Identity is binary against the written specification; a close trade name is not a pass.
References
- PMID:15817669 — Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog — Endocrinology — 2005
- PMID:21204297 — Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation — Drug Test Anal — 2010
- PMID:21871962 — Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls — Methods — 2012
- PMID:30489688 — An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma — Drug Test Anal — 2019
- PMID:30938069 — A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS — Drug Test Anal — 2019
- PMID:34665524 — Advances in the detection of growth hormone releasing hormone synthetic analogs — Drug Test Anal — 2021
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
